Liquid biopsy has emerged as a promising avenue for non‐invasive and rapid retrieval of
pathological information from patient body fluids. Over the years, liquid biopsy has garnered …

Over the last decade, great advancements have been made in the field of liquid biopsy
through extensive research and the development of new technologies that facilitate the use …

We previously described an approach called RealSeqS to evaluate aneuploidy in plasma
cell-free DNA through the amplification of~ 350,000 repeated elements with a single primer …

Cell-free DNA (cfDNA) sequencing has demonstrated great potential for early cancer
detection. However, most large-scale studies have focused only on either targeted …

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early
detection face challenges in test performance, due mostly to the limited abundance of ctDNA …

Background and objective Circulating tumor DNA (ctDNA) can be used for sensitive
detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in …

Circulating cell-free mitochondrial DNA (ccf-mtDNA) has emerged as a promising biomarker,
with potential implications for disease diagnosis. Changes in mtDNA, such as deletions …

Cell-free DNA (cfDNA) can be found in the blood and contains tumor-derived fragments
[circulating tumor DNA (ctDNA)] when extracted from cancer patients. In advanced-stage …

Plasma circulating tumor DNA (ctDNA) sequencing has demonstrated clinical utility for tumor
molecular profiling at initial diagnosis or tumor progression in advanced solid cancers and is …

Background Liquid biopsy testing, especially molecular tumor profiling of circulating tumor
DNA (ctDNA) in cell-free plasma, has received increasing interest in recent years as it …